Anti-trust lawsuit against Natco Pharma over generic cancer drug dismissed in US

Natco Pharma on December 21  said anti-trust claims against it regarding a generic cancer treatment drug in the US have been dismissed. In September this year, the company had stated that along with Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc and others, it had been named defendants by Louisiana Health Service & Indemnity Company, D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc, regarding anti-cancer treatment medication Pomalidomide.

“The plaintiffs voluntarily dismissed Breckenridge Pharmaceutical Inc and Natco Pharma Ltd from the case. All claims against the company in the litigation have now been dismissed,” Natco Pharma said in a regulatory filing. Breckenridge is the ANDA (Abbreviated New Drug Application) holder and front-end marketing partner for the Pomalidomide capsules generic product in the US, it added.

Natco’s Pomalidomide capsules generic product has not yet launched in the US, the company said.

Related Posts

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid